Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Dao, Kim-Hien T., Gotlib, Jason, Deininger, Michael M.N., Oh, Stephen T., Cortes, Jorge E., Collins, Robert H., Winton, Elliot F., Parker, Dana R., Lee, Hyunjung, Reister, Anna, Schultz, Savage, Samantha, Stevens, Brockett, Chase, Subbiah, Nan, Press, Richard D., Raess, Philipp W., Cascio, Michael, Dunlap, Jennifer, Chen, Yiyi, Degnin, Catherine, Maxson, Julia E., Tognon, Cristina E., Macey, Tara, Druker, Brian J., Tyner, Jeffrey W.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
RAPID COMMUNICATIONS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106977/
https://ncbi.nlm.nih.gov/pubmed/31880950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00895
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires